In a cohort of 66 patients with metastatic HER2+ BC treated with trastuzumab alone or trastuzumab and chemotherapy, patients with elevated markers of systemic inflammation prior to treatment demonstrated worse progression-free survival and shorter OS [71]. This evidence concerns the gene ERBB2 and breast cancer.